Summit Therapeutics Inc (NASDAQ:SMMT) currently has a daily average trading volume of 5.05M but it saw 2280574 shares traded in last market. With a market cap of 13.47B USD, the company’s current market price of $18.59 came falling about -0.32 while comparing to the previous closing price of $18.65. In past 52 weeks, the stock remained buoying in the range of price level as high as $33.89 and as low as $1.64. In the recent trading on the day, stock has struck highest price mark of $18.095 while lowest mark touched by it was $19.42.
Taking a look at 20-day trading activity of Summit Therapeutics Inc (SMMT) gives us an average price of $20.33, while its current price level is -45.15% below from 52-week high level whereas it is 1033.54% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $19.85 while that of 200 days or SMA-200 reads an average of $9.55. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.80% during that period while stretching the period over a month that decreases to 8.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 43.92 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Citigroup which downgraded the stock as “Neutral” in its note to investors issued on September 27, 2024, recommending a price target of between $19 and $23 for it. Citigroup issued its recommendations for the stock as it initiated the price target for the stock is $7.
Over the week, SMMT’s stock price is moving -4.47% down while it is -4.86% when we observe its performance for the past one month. Year-to-date it is 612.26% up and over the past year, the stock is showing an upside performance of 858.25%.
The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of -0.07 while estimate for next year EPS is -0.28.
Currently, Summit Therapeutics Inc’s total number of outstanding shares is 701.66M. Company’s return on investment (ROI) stands at -98.33% and return on equity (ROE) at -73.24%. Stock’s beta reads -0.96. Stock has a price to book (P/B) ratio of 69.03. Its return on asset (ROA) is -54.56% on average.
